Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹782.40down ₹5.15 (0.65%)BSE ₹782.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹787.55.
30 Oct: open ₹792.05, high ₹800.90, low ₹779.50
52-week range of traded prices to 30 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,348 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,21,54744.0% delivered
Natco Pharma share news and announcements
1,035 announcements, routine notices left out, newest first. Page 11 of 21.
Feb 2018
14 Feb · News Verification
Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned "USFDA inspection at co's Mekaguda facility in Telangana underway". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.7 Feb · Legal
Exchange has sought clarification from Natco Pharma Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated limited review report not submitted. The response of the Company is awaited.6 Feb · Corporate action
6 Feb · Results
2 Feb · Analysts
Jan 2018
22 Jan · Disclosure
Dec 2017
15 Dec · Committee Meeting Updates
14 Dec · Committee Meeting Updates
11 Dec · Board meeting
Nov 2017
3 Nov · Limited Review Report
2 Nov · Board meeting
2 Nov · Results
Oct 2017
31 Oct · Analysts
Sep 2017
Aug 2017
16 Aug · Updates
7 Aug · Corporate action
7 Aug · Board meeting
7 Aug · Results
2 Aug · Analysts
Jul 2017
Jun 2017
May 2017
30 May · Results
26 May · Analysts